Buparlisib (BKM120, NVP-BKM120)

Catalog No.S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 41 Publications

6 Customer Reviews

  • NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.

    Cell, 2017, 161(4):803-16. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017, 16(4):637-648. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MWfDfZRwfG:6aXOgRZN{[Xl? MUe3NkBp NGXPdGtFVVOR MljNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCHNUS1T{BufXSjboSge4l1cCCJSUWwJI9nKDBwMECwNVU5KM7:TR?= MWKyOFkxODJ4Nh?=
DU145 MXvDfZRwfG:6aXOgRZN{[Xl? M1j4dlczKGh? NY\udpltTE2VTx?= MmTTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCOS1KxJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMEC0N|Uh|ryP MWiyOFkxODJ4Nh?=
A2780 NYqzU4NwS3m2b4TvfIlkKEG|c3H5 MYe3NkBp MlK1SG1UVw>? MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCDMke4NEBk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2N|Uh|ryP NF64OGYzPDlyMEK2Oi=>
U87MG NGXudJZEgXSxdH;4bYMhSXO|YYm= MV63NkBp MULEUXNQ MnnCR5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlk5KM7:TR?= MlS0NlQ6ODB{Nk[=
A2780 NX;yOIxZTnWwY4Tpc44hSXO|YYm= MmPqNUBp NYTsUm86TE2VTx?= NVjTfpRRUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlA2PSEQvF2= M{fsflI1QTByMk[2
DU145 NWTqeZVXTnWwY4Tpc44hSXO|YYm= NITiWJEyKGh? M3fyO2ROW09? M37WdmlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBFXTF2NTDj[YxteyCqYYLic5JqdmdiTFvCNUBufXSjdHnvckB4cXSqIFXDOVAhd2ZiMD6wO|Mh|ryP MoTuNlQ6ODB{Nk[=
A2780 NYHTUpF5TnWwY4Tpc44hSXO|YYm= M2rReFEhcA>? MV3EUXNQ M{HCPWlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO|Qh|ryP NEn3NnMzPDlyMEK2Oi=>
MCF7 NWD5RYJiTnWwY4Tpc44hSXO|YYm= MlvSNUBp Mn7PSG1UVw>? NHTDZohKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hf2m2aDDFR|UxKG:oIECuNUDPxE1? M4\HeFI1QTByMk[2
U87MG NFjxOpVHfW6ldHnvckBCe3OjeR?= MkTMNUBp NXP6cZpQTE2VTx?= M2HqO2lvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFXDOVAhd2ZiMD6xN{DPxE1? NWPQWZhVOjR7MECyOlY>
A2780 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK3NkBp NUP1c5lLTE2VTx?= MoPUSWM2OD1yLkWyJO69VQ>? Mk[1NlQ6ODB{Nk[=
SKMES-1 NG[0dZNEgXSxdH;4bYMhSXO|YYm= NV21OZJ6OSEQvF2= NEHkS3U4OiCq M1PBXmlv\HWlZYOgZ4VtdCCmZXH0bC=> NIjH[XgzPjBzM{OxPC=>
H596 M{TlWWZ2dmO2aX;uJGF{e2G7 MX:xJO69VQ>? NVXWU4FZUW2yYXnyd{Bk\WyuIH3p[5JifGmxbh?= NUTpZWx5OjZyMUOzNVg>
HCC2450 NWS1TnI5TnWwY4Tpc44hSXO|YYm= M3j0SFEh|ryP M4nIb2lueGGrcoOgZ4VtdCCrbo\hd4lwdg>? NVrMVGlzOjZyMUOzNVg>
A549 NFv4fHFHfW6ldHnvckBCe3OjeR?= MY[1NFAhdk1? NUTLc|dnPDhiaB?= NHzQZnlFVVOR MU\Jcohq[mm2czDBb5Qh[WO2aY\heIlwdg>? M2DZWFI2QTN5Mkm5
A549 M3zQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv1WYpIOSEQvF2= NVHacXV3PzJiaB?= MmnPSG1UVw>? NWXy[HM3UW6qaXLpeJMh[2WubDDndo94fGh? M3zjelI2QTN5Mkm5
H522 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDWNUDPxE1? MmDXO|IhcA>? MoXSSG1UVw>? MWDJcohq[mm2czDj[YxtKGe{b4f0bC=> M1\a[lI2QTN5Mkm5
LNCaP NHv5eVVHfW6ldHnvckBCe3OjeR?= M2n3SlEh|ryP NXzIWIp1W3WycILld5NmeyCyLVHLWEBt\X[nbIO= MWmyOVM3ODd7OR?=
LNCaP95 NUDwOJpRTnWwY4Tpc44hSXO|YYm= M3y0SVEh|ryP MoDCV5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN? MmntNlU{PjB5OUm=
HCT-15 M4PufmFxd3Sxc3nzJGF{e2G7 NG\wbpIyOCEQvF2= NECwTFM1QCCq Mn3uSG1UVw>? MlHqTY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUG1JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MWCyOVE2OjJ2NR?=
HCT-116 M{nqcWFxd3Sxc3nzJGF{e2G7 NH34N2IyOCEQvF2= Mn;DOFghcA>? MYnEUXNQ MW\JcoR2[2W|IHHwc5B1d3OrczDpckBJS1RvMUG2JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? M1jnTVI2OTV{MkS1
NCI-H460 NILST4dCeG:2b4Ppd{BCe3OjeR?= M3zDN|ExKM7:TR?= M{D5RlQ5KGh? NHOySmxFVVOR NV3PeXRFUW6mdXPld{BieG:ydH;zbZMhcW5iTlPJMWg1PjBiY3XscJMhcGG{Yn;1dolv\yCSSVuzR2EhcG:2c4DveEBufXSjdHnvci=> NEH0ZlczPTF3MkK0OS=>
SKOV-3 NUDSdnhwSXCxdH;zbZMhSXO|YYm= MXKxNEDPxE1? NI\DRWc1QCCq NHHXSodFVVOR M2fRcWlv\HWlZYOgZZBweHSxc3nzJIlvKFONT2[tN{Bk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w NFfScHozPTF3MkK0OS=>
BSY-1 MmrnRZBwfG:|aYOgRZN{[Xl? NXzPbWNoOTBizszN NYL3clJ5PDhiaB?= MVHEUXNQ MVrJcoR2[2W|IHHwc5B1d3OrczDpckBDW1lvMTDj[YxteyCqYYLic5VzcW6pIGDJT|NESSCqb4TzdI91KG23dHH0bY9v M4nJSVI2OTV{MkS1
MKN-1 NETmeIpCeG:2b4Ppd{BCe3OjeR?= Ml24NVAh|ryP MkG3OFghcA>? M1nsS2ROW09? NILmeolKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCPS16tNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w NFf5Ro0zPTF3MkK0OS=>
NCI-H522 NEWxeHVCeG:2b4Ppd{BCe3OjeR?= MnrpNVAh|ryP M1f0Z|Q5KGh? MVPEUXNQ Mo\MTY5lfWOnczDhdI9xfG:|aYO= NH6yTY8zPTF3MkK0OS=>
OVCAR-3 M4PKbWFxd3Sxc3nzJGF{e2G7 MU[xNEDPxE1? MUK0PEBp MorvSG1UVw>? MYXJcoR2[2W|IHHwc5B1d3Orcx?= NF7HfG8zPTF3MkK0OS=>
HBC-5 MVHBdI91d3OrczDBd5NigQ>? MVWxNEDPxE1? NGr3[ZQ1QCCq NYPtd4ZoTE2VTx?= MX3JcoR2[2W|IHHwc5B1d3Orcx?= NXvIPWJzOjVzNUKyOFU>
RXF-631L Mn60RZBwfG:|aYOgRZN{[Xl? NV7FUpdTOTBizszN MWC0PEBp MXvEUXNQ NIr6T2lKdmS3Y3XzJIFxd3C2b4Ppdy=> MmHTNlUyPTJ{NEW=
MKN-45 NFvHdYRCeG:2b4Ppd{BCe3OjeR?= MmWxNVAh|ryP Mo\mOFghcA>? M1TBWmROW09? MYTJcoR2[2W|IHHwc5B1d3Orcx?= NUPYUodzOjVzNUKyOFU>
BON-1 NYnhUYdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDOUI1pPTByIH7N NGn5cZoyOCCm MUTEUXNQ NYTLPIppUW6qaXLpeJMh[2WubDDndo94fGh? MnPxNlUxOjZ{OUK=
BON-1 M4jlPWZ2dmO2aX;uJGF{e2G7 NHvCc2g2ODBibl2= MlnROEBp MmTxSG1UVw>? MmXqTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= MV6yOVAzPjJ7Mh?=
QGP-1 M4C4NGZ2dmO2aX;uJGF{e2G7 NFG0O|A2ODBibl2= MWC0JIg> M2XEO2ROW09? NIS4WIVKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez NWXwe5lOOjVyMk[yPVI>
Huh7 NYLibmhDTnWwY4Tpc44hSXO|YYm= M4DD[VEh|ryP NGXyZ3AyKGh? MoLDSG1UVw>? NUXmUnpPUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBU\XJ2N{S= M1P0dVI2ODB2NECz
BNL MVTGeY5kfGmxbjDBd5NigQ>? MmPUNUDPxE1? MoLONUBp Mn;qSG1UVw>? NFW5elJKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhWzZ? Mk[zNlUxODR2MEO=
MDA-MB-175 MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f2VlEh|ryP MoDEOUBl M1LBSmROW09? NFn1TFZKSzVyPEGg{txO NXTBO4ZHOjR6N{m3PVY>
MDA-MB-134 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHRZ3EyKM7:TR?= MX[1JIQ> MX;EUXNQ MXnJR|UxRDFizszN NXvXPXllOjR6N{m3PVY>
HCC1500 MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHaXlQ1OSEQvF2= M3T3blUh\A>? M4PyNGROW09? MU\JR|UxRDFizszN NF;EbJAzPDh5OUe5Oi=>
EFM-19 NGPMUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPYNUDPxE1? MUO1JIQ> MV\EUXNQ NGDFc4NKSzVyPEGg{txO MmfrNlQ5Pzl5OU[=
ZR-75-30 NIH6VHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3KW415OSEQvF2= M{jLdlUh\A>? NV;EdHEyTE2VTx?= NEjiVXRKSzVyPEGg{txO NEWyWZEzPDh5OUe5Oi=>
MDA-MB-361 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[wPVEh|ryP M165blUh\A>? M4jP[GROW09? M1rMV2lEPTB:MTFOwG0> MmPCNlQ5Pzl5OU[=
T-47D MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHiNUDPxE1? NYj1O3NJPSCm MWLEUXNQ M3LJW2lEPTB:MTFOwG0> M{\rN|I1QDd7N{m2
SK-BR-3 M2TnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7SNUDPxE1? MVS1JIQ> Mof5SG1UVw>? MXnJR|UxRDFizszN MVmyOFg4QTd7Nh?=
UACC-732 MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH25fm8yKM7:TR?= M3u4VFUh\A>? NXXTblMxTE2VTx?= MnPNTWM2ODxzIN88US=> MVuyOFg4QTd7Nh?=
BT-474 M3TGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTvNUDPxE1? NYiwO3JPPSCm NFPWfGVFVVOR Ml\TTWM2ODxzIN88US=> M1TmSFI1QDd7N{m2
HCC202 M13Yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITLOHQyKM7:TR?= MXG1JIQ> NXLQU3FxTE2VTx?= M4DFZmlEPTB:MTFOwG0> NEfpN3ozPDh5OUe5Oi=>
MCF7 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFGw[lYyKM7:TR?= NXvZeYdFPSCm MWXEUXNQ NFHFTWhKSzVyPEGg{txO MmDFNlQ5Pzl5OU[=
MDA-MB-415 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\lNUDPxE1? MUK1JIQ> MoDqSG1UVw>? M2ixfmlEPTB:MTFOwG0> MX6yOFg4QTd7Nh?=
MDA-MB-453 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnHNUDPxE1? MkfxOUBl MkjnSG1UVw>? MU\JR|UxRDFizszN NX7GW3BjOjR6N{m3PVY>
ZR-75-1 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWxJO69VQ>? NEX2RmE2KGR? Mkn4SG1UVw>? M2L4TmlEPTB:MTFOwG0> Mn7pNlQ5Pzl5OU[=
HCC38 NUCw[HdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWxJO69VQ>? M1zMV|Uh\A>? MWfEUXNQ NFnMdG1KSzVyPEGg{txO MlHCNlQ5Pzl5OU[=
HCC1419 MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS5S29SOSEQvF2= NFTCZ242KGR? Mk[5SG1UVw>? M4niZWlEPTB:MTFOwG0> M1jFWFI1QDd7N{m2
UACC-812 NV3CXVRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\zWlEh|ryP M4nWdVUh\A>? NYGxfHliTE2VTx?= M12yO2lEPTB:MTFOwG0> NGLRO3YzPDh5OUe5Oi=>
HCC1187 MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHezO3oyKM7:TR?= Mn3POUBl MWLEUXNQ NGrQOHVKSzVyPEGg{txO MknuNlQ5Pzl5OU[=
KPL-1 NFrWboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP0NUDPxE1? NVrkZYY2PSCm MYfEUXNQ MoLrTWM2ODxzIN88US=> MnnJNlQ5Pzl5OU[=
SUM-225 NUnzU|RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTYTWUyKM7:TR?= MlLkOUBl MlzqSG1UVw>? M323WWlEPTB:MTFOwG0> NX7te3Z2OjR6N{m3PVY>
EFM-192A MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvDNUDPxE1? MXq1JIQ> NHHnZ3JFVVOR MWXJR|UxRDFizszN Mnf1NlQ5Pzl5OU[=
JIMT-1 NV7aRY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPPTZdYOSEQvF2= MWC1JIQ> MXHEUXNQ NUHr[IJuUUN3MEyxJO69VQ>? M2XwUlI1QDd7N{m2
HCC1143 Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHtXGMxOSEQvF2= M{\qelUh\A>? NHnUPXdFVVOR MlfQTWM2ODxzIN88US=> NX7ld5RNOjR6N{m3PVY>
HCC2218 M4nIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\RTW9[OSEQvF2= MWi1JIQ> NFvxTWRFVVOR NXHVeotOUUN3MEyxJO69VQ>? NHPsWnMzPDh5OUe5Oi=>
MDA-MB-468 MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[xJO69VQ>? MWG1JIQ> Mn;KSG1UVw>? MnO3TWM2ODxzIN88US=> M{PUSlI1QDd7N{m2
BT-20 NHjDOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCxJO69VQ>? MWG1JIQ> M4PsOmROW09? M{DRbmlEPTB:MTFOwG0> MoHsNlQ5Pzl5OU[=
MDA-MB-435 NXjje4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvEUplCOSEQvF2= MWq1JIQ> M4LtR2ROW09? NF3Eb|NKSzVyPEGg{txO NXzWNJVoOjR6N{m3PVY>
BT-549 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[zNUDPxE1? MWG1JIQ> Ml;pSG1UVw>? MVTJR|UxRDFizszN NHPHWGgzPDh5OUe5Oi=>
HCC1806 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmxJO69VQ>? NYDKS5dsPSCm MX3EUXNQ MVvJR|UxRDFizszN M3XiSVI1QDd7N{m2
HCC1937 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH6T3doOSEQvF2= NHe0RYY2KGR? MXrEUXNQ MoX1TWM2ODxzIN88US=> NGG0PZQzPDh5OUe5Oi=>
Hs578T NVLyfm02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKxJO69VQ>? MlKzOUBl NHn2[GNFVVOR M4i5eGlEPTB:MTFOwG0> NH\CcI0zPDh5OUe5Oi=>
LN18 M4L5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3ZZ41KOjBizszN M1rlSVczKGh? NV7MSJdrTE2VTx?= MV;JR|UxRDVizszN MVSyOFc1OTB5NB?=
LN229 MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL0VIl4OjBizszN MnLXO|IhcA>? MVjEUXNQ NH;wOJFKSzVyPEWg{txO NGLYUmszPDd2MUC3OC=>
LNZ308 NUHJenNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjWU2hwOjBizszN NIToUlE4OiCq MXLEUXNQ MnjlTWM2ODx3IN88US=> NWj5fVJtOjR5NEGwO|Q>
T98G NGf3UXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjCdWdZOjBizszN MmjOO|IhcA>? MnHtSG1UVw>? M2Px[WlEPTB:NTFOwG0> NELQfW4zPDd2MUC3OC=>
U87 NWfZZVY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELk[HgzOCEQvF2= M1LxRVczKGh? NVfTZ3hvTE2VTx?= MYHJR|UxRDVizszN MlHxNlQ4PDFyN{S=
LN18 NIPKRoZHfW6ldHnvckBCe3OjeR?= MmjCOUDPxE1? NYHQ[WZEOjRiaB?= M4TpeGROW09? Mm\DTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? MnvxNlQ4PDFyN{S=
LNZ308 NF;sc5NHfW6ldHnvckBCe3OjeR?= NHnibWI2KM7:TR?= NXHSO|dsOjRiaB?= NX7jOGRNTE2VTx?= NGXiTYhKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuW M4LqV|I1PzRzMEe0
Saos-2 NXrZZ4FmTnWwY4Tpc44hSXO|YYm= NGXDSWE2OCEQvF2= NX[1bGVnPDhiaB?= MX;Jcohq[mm2czDj[YxtKGmwdnHzbY9v M3uyfFI1PzJ5Nk[w
MG-63 MmjRSpVv[3Srb36gRZN{[Xl? NYPhT4dJPTBizszN NHPkSIk1QCCq Ml3VTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? NXSzNIN6OjR5Mke2OlA>
SJSA-1 MkfDSpVv[3Srb36gRZN{[Xl? Ml2xOVAh|ryP MUi0PEBp NUXCZW03UW6qaXLpeJMh[2WubDDpcpZie2mxbh?= NHHFbHMzPDd{N{[2NC=>
Saos-2 NX\nc5UzTnWwY4Tpc44hSXO|YYm= MYi1NEDPxE1? M3PWTFQ5KGh? NELXc5FKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v MlTFNlQ4Ojd4NkC=
MG-63 NHqzR3BHfW6ldHnvckBCe3OjeR?= NWHDeHU6PTBizszN M1vK[|Q5KGh? NGDiNGpKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v M3myN|I1PzJ5Nk[w
SJSA-1 MkTKSpVv[3Srb36gRZN{[Xl? MUS1NEDPxE1? MnXxOFghcA>? MVvJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO|aX;u NFG3blUzPDd{N{[2NC=>
Saos-2 MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVy1NEDPxE1? NHLwbXM1QCCq NIHDUlhKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M3fXd|I1PzJ5Nk[w
MG-63 M1vZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXxOVAh|ryP Mm\HOFghcA>? NFTZO4xKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M3v2eVI1PzJ5Nk[w
SJSA-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\iPVUxKM7:TR?= MknFOFghcA>? NXPDSWZmUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NWK3VXV3OjR5Mke2OlA>
FaDu NWLjZopLTnWwY4Tpc44hSXO|YYm= MkDqOUDPxE1? MXyyOEBp MYDEUXNQ NWizXoRMWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> Mkn0NlQ3OzFzNEe=
EMT6 MorGSpVv[3Srb36gRZN{[Xl? M2H2SFUh|ryP MmrPNlQhcA>? MmLMSG1UVw>? MVHS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= NEfWSHkzPDZ|MUG0Oy=>
HCT116 MmLZSpVv[3Srb36gRZN{[Xl? NGHsdZE2KM7:TR?= MUOyOEBp NUGwPVFZTE2VTx?= M3HlWnJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u M1zGblI1PjNzMUS3
U87 MomySpVv[3Srb36gRZN{[Xl? MYG1JO69VQ>? NVf4SlI5OjRiaB?= M3;tWWROW09? NHHFVXRT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> M4HyW|I1PjNzMUS3
GBM MnS5RZBweHSxc3nzJGF{e2G7 NHzObFcz|ryP NVjMeWdiPDiq NET0No1FVVOR NIDMVG1qdmS3Y3XkJIhq\2incjDs[ZZmdHNib3[gZZBweHSxc3nzMEBidmRiZHXjdoVie2WmIHPlcIwhfmmjYnnsbZR6 MXuyOFUxODR7Mh?=
BON MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvEZ4EyNTYQvF2= NITQU3M4Omh? M4LmfYRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> NILFdmczPDR2M{WyNy=>
BON MVHBdI9xfG:|aYOgRZN{[Xl? NXnoNmdbOS13zszN NVn5XlVPOjSq MkLvbY5kemWjc3XzJIFxd3C2b4Ppdy=> MVKyOFQ1OzV{Mx?=
H1975 NYfLTlZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLiVZN6OC5|LUmuOu69VQ>? M{HEXlczcA>? MUTEUXNQ Mm[xTWM2OD1zLkO4Oe69VQ>? MYKyOFM{Pzh2Nh?=
H1975 M37vNmFxd3C2b4Ppd{BCe3OjeR?= MVyy{txO NVXSfnc{OjSq MVnEUXNQ NW[yeHdocW6lcnXhd4V{KGGyb4D0c5NqeyC{YYTlJJNq\26rZnnjZY51dHl? M2LCNVI1OzN5OES2
T-ALL MYDBdI9xfG:|aYOgRZN{[Xl? MYDi[ZR4\WWwIEGuOEBidmRiNT6zJI1OKGG2IEK0bEBidmRiMD65JIFv\CB3LkWgcW0h[XRiNEjoJIlvKGSrZn\ldoVvfCClZXzsJIxqdmV? MkC0NlQhd3JiNEjo NVnuS2NyTE2VTx?= Ml\zZYZn\WO2czD0bIUhWEl|SzDwZZRpf2G7IHnuJHQuSUyOIHPlcIwhdGmwZYO= M4TGdVI1OzFyN{O2
BCR-ABL M2r6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHXNE4zPS1zMN88US=> NX\OPHFyPGR? MVzzbYdvcW[rY3HueIx6KGmwaHnibZQh[2WubDDwdo9tcW[ncnH0bY9v NILVR|YzPDJ2NE[xNi=>
LC-1/SQSF MnPuSpVv[3Srb36gRZN{[Xl? NUnsSHBsO87:TR?= MV6yOIg> MWjEUXNQ NHLVdHhl\WO{ZXHz[UBPWkZ{IIDyc5RmcW5ibHX2[Yw> MXeyN|k5ODB7Mx?=
Primary CLL cells MV7BdI9xfG:|aYOgRZN{[Xl? M1;WT|EuOTEQvF2= NUXlbWZWPDiq NEH6U2FqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCFTFygZ4VtdHNiaX7k[ZBmdmSnboSgc4YheHKxZ37vd5Rq[yCvYYLr[ZJ{ MnLQNlM5PTB6MEe=
Primary CLL cells M{HiXmtqdmG|ZTDBd5NigQ>? NH\6NZQz|ryP MlLhN|BucW5? Mn70[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? MlfKNlM5PTB6MEe=
Primary CLL cells M1TmOWN6fG:2b4jpZ{BCe3OjeR?= MoHBNu69VQ>? NX7RVGw{OjSq NXvYe2tHcW6mdXPld{Bk\WyuIHP5eI91d3irY3n0fS=> M3rTW|I{QDVyOEC3
human NSCLC cell lines NHLBbHlCeG:ydH;zbZMhSXO|YYm= M3PnXFAvOTJ3LUVOwG0> NXi0V3FtOjSq M4O3NWROW09? NI\JVGJKSzVyczDyZY5o\XNiZoLvcUAxNjRvMt88US=> MkOzNlM2PjJ2N{K=
human HCC cell lines NHjQ[GJE\WyuII\pZYJqdGm2eTDhd5NigQ>? NVjGVoFLOC5yMEWtNe69VQ>? NGHUOYU1QGh? Mnn2TWM2OD1zzszN NGPhOJgzOzR6OUm5PS=>
Huh7 NF3DSlJMcW6jc3WgRZN{[Xl? Ml7NNe69VQ>? Ml3uOFhp NXHsVpp2e2mpbnpvsKFk[W62bImgdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gRYt1 MYKyN|Q5QTl7OR?=
SK-HEP1 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPlOmkyNTJyzszN MlLpO|Jp NVLzbmpMTE2VTx?= MnzqTWM2OO,:nEJOwG0> NUXL[GlbOjN2N{mxN|Y>
786-0 NVK5OYFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OwU|EuOjEQvF2= MlHxO|Jp M2m1fWROW09? M2\5RmlEPTExvKyx{txO NGjVZWwzOzR5OUGzOi=>
JVM2 Mm\HR5l1d3SxeHnjbZR6KGG|c3H5 Moi5NE4zNTJyzszN NF[1cJk4Omh? NXXEVIF3TE2VTx?= MoSxTWM2OD1yLkpOwG0> MWqyN|I{QDZ|OR?=
EHEB NXLNbXE{S3m2b4TvfIlkcXS7IHHzd4F6 MWewMlIuOjEQvF2= MXK3Nog> M4LWZWROW09? MXPJR|UxRTBwN988US=> MkXONlMzOzh4M{m=
MEC2 M371e2N6fG:2b4jpZ4l1gSCjc4PhfS=> NWfVU3dCOC5{LUKw{txO NIfGPJQ4Omh? MXfEUXNQ M{DJOGlEPTB;MD63{txO M{TTOlI{OjN6NkO5
primary B-CLL lymphocytes NES4e4xCeG:ydH;zbZMhSXO|YYm= MXXJR|UxKG[xcjDlZYNpKHC{aX3hdpkh[2WubDDsbY5m NYnlcVJCOjSq MoPVSG1UVw>? M{DQ[2lEPTExvKyz{txOKG[xcjDhcIwheGG2aXXueJM> NXHtcWY6OjN{M{i2N|k>
primary B-CLL lymphocytes MUfLbY5ie2ViQYPzZZk> MmH0TWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>? Ml7iNlRp NH7WflNqdmirYnn0d{BxPzCVNlugKkA1TS2EUEGg[ZhxemW|c3nvci=> MUWyN|I{QDZ|OR?=
human NSCLC MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;jWpQxNjVvMt88US=> MoD1O|Jp MkTJTWM2OD1zzszN NIrqd48zOjd6MUO5Ny=>
human NSCLC Ml30T4lv[XOnIFHzd4F6 M4S3[|HPxE1? MVyyOIg> NV;kdGk6cW6qaXLpeJMhfGinIFHreE9uXE:UIIPp[45idGmwZzDwZZRpf2G7IHH0JFNpKGGodHXyJJRz\WG2bXXueC=> NWm4UZNTOjJ5OEGzPVM>
Y1 cell line NGXreIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzLNE4y|ryPL{JOwG0> M4X1U|I1cA>? NXzkV5NFTE2VTx?= M3n6TIlvcGmkaYTzJFYx97zHIHPlcIwhfmmjYnnsbZR6KGmwIF35Z{1U[3S{LYTyZY5{\mWldHXkJINmdGy| MV[yNlY6OjlyNB?=
PIK3CA-mutant MCF7 NUexRVBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljWS2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1? NWrhWpQ1PzKq MXjHTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO|NvVQ>? MVKyNlY2Ozl4Nx?=
PIK3CA-mutant MCF7 M1rn[WtqdmG|ZTDBd5NigQ>? MoD6TWM2OD1zMUVCtVNvVQ>? MXO3Nog> MUfJR|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:|cHjvdplt[XSrb36gcIV3\Wy| MYmyNlY2Ozl4Nx?=
MCF7-myr-Akt M3\GVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zkVGdKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P M4HhPFczcA>? NXnCWGwyT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= MoH4NlI3PTN7Nke=
colon cancer cell lines NGfwSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXBW2ZHOC1zMN88US=> M{fpNFczcA>? NILlRnlFVVOR MnnqTWM2OD1zzszN MmHINlI2PDN6NUe=
gastric cancer cell lines NGPlTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;D[|AuOTEQvF2= NIr0eYI4Omh? NHTlSZZFVVOR MWXJR|UxRTJvNd88US=> MnHINlI2PDN6NUe=
HCT-116/HT-29/MKN-45 NXTqNo1USXCxcITvd4l{KEG|c3H5 NUnR[FFVOs7:TR?= MYG0PIg> NF7XSHd{cGmodDDpckBIOiCyaHHz[S=> M{KyN|IzPTR|OEW3
HT-29 and HCT-116 M1;UO2Nie3Cjc3WgZZN{[Xl? NIi1Umw2|ryP NFjTXYQzPGh? MXXpcoR2[2W|IHPhd5Bie2ViYXP0bZZqfHl? MV[yNlU1Ozh3Nx?=
MM cell lines M{PpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LJe|Ex|ryP NHjHUG4zPGh? NEftcFJFVVOR MWnJR|UxKH[jcnnld{BidW:wZzDkbYZn\XKnboSgZ4VtdCCuaX7ld{BqdiC2aX3lJIFv\CCmb4PlJIRmeGWwZHXuZ4U> MWeyNlIxPzR6NR?=
ARP-1 MX\BdI9xfG:|aYOgRZN{[Xl? MVuxNO69VQ>? Moq3NlRp MUXEUXNQ M3uyNYlv\HWlZYOgUW0h[2WubDDhdI9xfG:|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36= M2f6WlIzOjB5NEi1
SNU-601 Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfPVlhFPzKq MWfEUXNQ M2TjNmlEPTB;MD64NVbDuTBwME[z{txO NEK5T40zOjF3OUixOC=>
SNU-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;nUpM4Omh? MmDkSG1UVw>? MVLJR|UxRTFwMEiyxtExNjB{ON88US=> NHPSdHUzOjF3OUixOC=>
SNU-668 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXryZ|h7PzKq M4jD[WROW09? MVnJR|UxRTFwNUe5xtExNjB5NN88US=> MXKyNlE2QThzNB?=
AGS NUHOdHJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHDNZRiPzKq MmnuSG1UVw>? NIPINJRKSzVyPUGuO|E1yrFyLkGxO:69VQ>? NXH6RoprOjJzNUm4NVQ>
SNU-216 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS1ZXV3PzKq MoLISG1UVw>? M3T0NWlEPTB;Mj62PVLDuTBwMEiy{txO NEm0VFkzOjF3OUixOC=>
SNU-5 M{\BZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVO3Nog> NHro[I1FVVOR M3fVNGlEPTB;MT6zOVHDuTBwMEmx{txO NHLIb5czOjF3OUixOC=>
SNU-638 NHPEXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTFNHQ4Omh? M1q2NGROW09? M3\rTWlEPTB;Mj6yPFLDuTBwMEWz{txO MmToNlIyPTl6MUS=
SNU-16 NWXLV4t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjTO5dDPzKq MYHEUXNQ M3HmbGlEPTB;MT61O|PDuTBwMECx{txO NHrqOG0zOjF3OUixOC=>
SNU-484 NUDVS255T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnYR5NJPzKq MofJSG1UVw>? NITzVIdKSzVyPUGuO|I5yrFyLkC0Oe69VQ>? M3Xs[lIzOTV7OEG0
SNU-620 M1u1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjEO|Jp M4ThWWROW09? NH;MSmZKSzVyPUKuPVM6yrFyLkCwNe69VQ>? NEHMe2IzOjF3OUixOC=>
SNU-719 NGHzcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fq[FczcA>? MlzrSG1UVw>? Mmr2TWM2OD1|LkCzO:KyOC5yM{NOwG0> NEfJ[HozOjF3OUixOC=>
glioma cell lines MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[0T4Q4Omh? MmLLTWM2OD1zLUNOwG0> MnrqNlIxPjVyOEC=
U87 Ml;URZBweHSxc3nzJGF{e2G7 MV2y{txO NXf6d3ZNPzKq MmLXbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCjbnSgZ4xm[X[nZDDQRXJRKGGwZDDjZZNx[XOnLUO= NUGwPVN2OjJyNkWwPFA>

... Click to View More Cell Line Experimental Data

In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay:[1]
+ Expand

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:[1]
+ Expand
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Formulation: In 15% Captisol.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) supplier | purchase Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) cost | Buparlisib (BKM120, NVP-BKM120) manufacturer | order Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID